Samsung Bioepis shoots down Janssen patent for ulcerative colitis biologic

Intellectual Property 2025-10-09 11:59 pm By Cat Fredenburgh

Samsung Bioepis has successfully opposed Janssen’s bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.